



March 17, 2026

Company name	CellSource Co., Ltd.
Name of representative	Masayuki Yamakawa, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information for inquiries	Tomohiro Iga, Director and CFO Tel: +81-3-6455-5308

Notice Regarding Approval of Transition to the TSE Standard Market and Withdrawal of the Plan to Meet the Continued Listing Criteria

CellSource Co., Ltd. (the "Company") hereby announced that at its Board of Directors meeting held on January 28, 2026, it resolved to apply for a transition of its market segment to the Standard Market of the Tokyo Stock Exchange (the "TSE") and disclosed this decision on the same day. Today, the Company received approval for this transition of market segment from the TSE. As a result, the Company will change its market segment to the TSE Standard Market as of March 24, 2026.

Furthermore, as the Company did not meet the continued listing criterion for "tradable share market capitalization" for the Prime Market as of October 31, 2025, the Company disclosed its "Plan to Meet the Continued Listing Criteria (Entering the Improvement Period)" on January 28, 2026. However, following the approval of the transition to the Standard Market, the Company will withdraw the said plan as of today.

Even after the transition to the Standard Market, the Company will continue to strive toward its mission of "social implementation of regenerative medicine". In the Standard Market, which maintains a certain level of governance and liquidity, we will aim to strengthen our profitability with an awareness of the cost of capital. By directly linking business growth to the enhancement of medium to long-term corporate value, we will strive to meet the expectations of all our stakeholders.

We would like to express our sincere gratitude to our shareholders and investors for their understanding and ask for their continued support and guidance.

Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete. In the event of any translation error or misunderstanding, the original Japanese version shall prevail.